Iclaprim

Drug Profile

Iclaprim

Alternative Names: AR-100; MTF-100; Ro-48-2622

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Arpida; Evolva Holding SA; Motif Bio
  • Class Antibacterials; Pyrimidines; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Methicillin-resistant Staphylococcus aureus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase I Nosocomial infections
  • Preclinical Methicillin-resistant Staphylococcus aureus infections
  • Suspended Nosocomial pneumonia
  • Discontinued Chlamydial infections; Gonorrhoea

Most Recent Events

  • 15 Sep 2017 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in United Kingdom (IV)
  • 15 Sep 2017 Iclaprim receives Orphan Drug status for Methicillin-resistant Staphylococcus aureus infections in USA
  • 08 Aug 2017 Motif Bio completes the phase III REVIVE-2 trial for Skin and soft tissue infections in USA, Argentina, Belgium, Croatia, Cuba, Czech Republic, Estonia, Hungary, Portugal, Romania, Turkey (IV) (NCT02607618)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top